Lyell Immunopharma (NASDAQ:LYEL) CEO Lynn Seely Sells 438 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely sold 438 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $23.12, for a total transaction of $10,126.56. Following the completion of the transaction, the chief executive officer owned 81,721 shares of the company’s stock, valued at approximately $1,889,389.52. The trade was a 0.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Lyell Immunopharma Stock Up 2.7%

Shares of LYEL stock traded up $0.63 during trading hours on Wednesday, reaching $24.34. 97,228 shares of the stock traded hands, compared to its average volume of 84,515. The firm has a market capitalization of $516.98 million, a PE ratio of -1.06 and a beta of -0.14. Lyell Immunopharma, Inc. has a 1-year low of $7.65 and a 1-year high of $45.00. The business has a fifty day moving average price of $27.98 and a 200 day moving average price of $19.60.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.81) by $0.68. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.01 million. Research analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on LYEL shares. HC Wainwright upgraded Lyell Immunopharma from a “neutral” rating to a “buy” rating and lifted their price target for the company from $20.00 to $45.00 in a report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $45.00.

Institutional Trading of Lyell Immunopharma

Several hedge funds and other institutional investors have recently modified their holdings of LYEL. BBR Partners LLC purchased a new position in Lyell Immunopharma in the fourth quarter valued at about $210,000. Goldman Sachs Group Inc. purchased a new stake in shares of Lyell Immunopharma during the 4th quarter worth about $2,976,000. Geode Capital Management LLC increased its holdings in Lyell Immunopharma by 25.1% in the fourth quarter. Geode Capital Management LLC now owns 162,997 shares of the company’s stock worth $5,020,000 after buying an additional 32,740 shares during the last quarter. Millennium Management LLC raised its position in Lyell Immunopharma by 140.0% during the third quarter. Millennium Management LLC now owns 125,361 shares of the company’s stock valued at $2,036,000 after acquiring an additional 73,132 shares in the last quarter. Finally, Foresite Capital Management V LLC lifted its stake in Lyell Immunopharma by 17.3% in the third quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company’s stock valued at $7,748,000 after acquiring an additional 70,426 shares during the last quarter. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.